We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens.
- Authors
Ken Saijo; Hiroo Imai; Kota Ouchi; Keiju Sasaki; Yuya Yoshida; Yoshifumi Kawamura; Sakura Taniguchi; Yuki Kasahara; Keigo Komine; Hidekazu Shirota; Masanobu Takahashi; Chikashi Ishioka
- Abstract
Background: Pembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear. Methods: This study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients’ characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed. Results: The 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and −9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= −0.41, p=0.0017; PFS: r=−0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤−45 was associated with better OS and PFS. Conclusion: DpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.
- Subjects
SENDAI-shi (Miyagi-ken, Japan); HEAD &; neck cancer; MEDIAN (Mathematics); IMMUNE checkpoint inhibitors; OVERALL survival; MULTIVARIATE analysis
- Publication
Frontiers in Oncology, 2023, p01
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2023.1230731